LIFR and breast carcinoma: The time of exposure and concentration of the inhibitor were based on the previous use of STAT3-IN-1 in human mammary carcinoma cell lines.23 The assay results showed that the pharmacological inhibition of STAT3 activation also significantly affected the activation of the LIFR reporter (Figure 3c).